Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.96−0.04 (-0.80%)
Close on Nov 17, 2026Market cap $193.13MP/E –Yield –
Entrada Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Entrada Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $4.69M, down 94.1% year over year. For fiscal 2025 it was $25.42M, down 87.9% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.42M | -87.9% |
| FY2024 | Dec 31, 2024 | $210.78M | +63.4% |
| FY2023 | Dec 31, 2023 | $129.01M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $898.00K | -53.9% |
| Q1 FY2026 | Mar 31, 2026 | $875.00K | -95.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.30M | -96.5% |
| Q3 FY2025 | Sep 30, 2025 | $1.61M | -91.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.95M | -97.9% |
| Q1 FY2025 | Mar 31, 2025 | $20.56M | -65.2% |
| Q4 FY2024 | Dec 31, 2024 | $37.40M | -10.6% |
| Q3 FY2024 | Sep 30, 2024 | $19.57M | -55.3% |
| Q2 FY2024 | Jun 30, 2024 | $94.69M | +421.2% |
| Q1 FY2024 | Mar 31, 2024 | $59.12M | +134.0% |
| Q4 FY2023 | Dec 31, 2023 | $41.85M | – |
| Q3 FY2023 | Sep 30, 2023 | $43.74M | – |
| Q2 FY2023 | Jun 30, 2023 | $18.17M | – |
| Q1 FY2023 | Mar 31, 2023 | $25.26M | – |
| Q3 FY2022 | Sep 30, 2022 | $0 | – |
| Q2 FY2022 | Jun 30, 2022 | $0 | – |
| Q1 FY2022 | Mar 31, 2022 | $0 | – |
See a number that looks wrong?